Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: Basic mechanisms to potential therapies

Annals of Thoracic Surgery

Volumn 78, Issue 1, 2004, Pages 360-368

  Tsai, Ben M ^a   Wang, Meijing ^a   Turrentine, Mark W ^a   Mahomed, Yousuf ^a   Brown, John W ^a   Meldrum, Daniel R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Emerson Hall 215 ^*  (United States)

Author keywords

9

Indexed keywords

BOSENTAN; ENDOTHELIUM DERIVED RELAXING FACTOR; ILOPROST; ION CHANNEL; NITRIC OXIDE; PROSTACYCLIN;

CELL DAMAGE; CELL DEATH; CLINICAL TRIAL; HUMAN; HYPOXEMIA; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; METHEMOGLOBINEMIA; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; THORAX SURGERY; VASODILATATION;

ADAPTATION, PHYSIOLOGICAL; ADULT; ANIMALS; ANOXEMIA; ANOXIA; CARDIAC SURGICAL PROCEDURES; CHILD; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; OXYGEN; POTASSIUM CHANNELS; PROSTAGLANDINS; PULMONARY ARTERY; PULMONARY CIRCULATION; RATS; RESPIRATORY DISTRESS SYNDROME, ADULT; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION;

EID: 3042581845     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2003.11.035     Document Type: Review

References (105)

1. Sheridan B.C., McIntyre R.C., Meldrum D.R., Meng X., Fullerton D.A. Endotoxin stuns cGMP-mediated pulmonary vasorelaxation. Shock. 8:1997;207-212
2. Sheridan B.C., McIntyre R.C., Meldrum D.R., Fullerton D.A. Phosphodiesterase inhibition overcomes pulmonary vasomotor dysfunction in acute lung injury. J Surg Res. 71:1997;145-149
3. Sheridan B.C., McIntyre R.C., Meldrum D.R., Fullerton D.A. Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury. J Surg Res. 71:1997;150-154
4. ATP channels contribute to beta- and adenosine receptor-mediated pulmonary vasorelaxation. Am J Physiol. 273:1997;L950-956
5. Jardin F., Gurdjian F., Delille F., Margairaz A. Pulmonary hypertension in the adult respiratory distress syndrome (ARDS). Intensive Care Med. 5:1979;155-156
6. Hopkins R.A., Bull C., Haworth S.G., de Leval M.R., Stark J. Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg. 5:1991;628-634
7. Waldman J.D., Lamberti J.J., Mathewson J.W., et al. Congenital heart disease and pulmonary artery hypertension. I. Pulmonary vasoreactivity to 15% oxygen before and after surgery. J Am Coll Cardiol. 2:1983;1158-1164
8. Kimblad P.O., Green K., Sjoberg T., Steen S. Prostanoid release after lung transplantation. J Heart Lung Transplant. 15:1996;999-1004
9. Robin E.D., Theodore J., Burke C.M., et al. Hypoxic pulmonary vasoconstriction persists in the human transplanted lung. Clin Sci (Lond). 72:1987;283-287
10. Von Euler U.S., Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand. 12:1946;301-320
11. Barnes P.J., Liu S.F. Regulation of pulmonary vascular tone. Pharmacol Rev. 47:1995;87-131
12. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376
13. Meldrum D.R., McIntyre R.C., Sheridan B.C., et al. l-Arginine decreases alveolar macrophage proinflammatory monokine production during acute lung injury by a nitric oxide synthase-dependent mechanism. J Trauma. 43:1997;888-893
14. Meldrum D.R., Shames B.D., Meng X., et al. Nitric oxide downregulates lung macrophage inflammatory cytokine production. Ann Thorac Surg. 66:1998;313-317
15. Haynes W.G., Webb D.J. The endothelin family of peptides local hormones with diverse roles in health and disease? Clin Sci (Lond). 84:1993;485-500
16. Kato M., Staub N.C. Response of small pulmonary arteries to unilobar hypoxia and hypercapnia. Circ Res. 19:1966;426-440
17. Bennie R.E., Packer C.S., Powell D.R., Jin N., Rhoades R.A. Biphasic contractile response of pulmonary artery to hypoxia. Am J Physiol. 261:1991;L156-163
18. Jin N., Packer C.S., Rhoades R.A. Pulmonary arterial hypoxic contraction signal transduction. Am J Physiol. 263:1992;L73-78
19. Karamsetty M.R., Klinger J.R., Hill N.S. Evidence for the role of p38 MAP kinase in hypoxia-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 283:2002;L859-866
20. Robertson T.P., Hague D., Aaronson P.I., Ward J.P. Voltage-independent calcium entry in hypoxic pulmonary vasoconstriction of intrapulmonary arteries of the rat. J Physiol (Lond). 525:2000;3669-3680
21. Woodmansey P.A., Zhang F., Channer K.S., Morice A.H. Effect of the calcium antagonist amlodipine on the two phases of hypoxic pulmonary vasoconstriction in rat large and small isolated pulmonary arteries. J Cardiovasc Pharmacol. 25:1995;324-329
22. Ward J.P., Robertson T.P. The role of the endothelium in hypoxic pulmonary vasoconstriction. Exp Physiol. 80:1995;793-801
23. Lazor R., Feihl F., Waeber B., Kucera P., Perret C. Endothelin-1 does not mediate the endothelium-dependent hypoxic contractions of small pulmonary arteries in rats. Chest. 110:1996;189-197
24. 2+ sensitization during sustained hypoxic pulmonary vasoconstriction is endothelium dependent. Am J Physiol Lung Cell Mol Physiol. 284:2003;L1121-1126
25. Archer S.L., Tolins J.P., Raij L., Weir E.K. Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium-derived relaxing factor. Biochem Biophys Res Commun. 164:1989;1198-1205
26. + channel openers, aprikalim and pinacidil, on hypoxic pulmonary vasoconstriction. Eur J Pharmacol. 263:1994;17-23
27. Thompson B.T., Steigman D.M., Spence C.L., Janssens S.P., Hales C.A. Chronic hypoxic pulmonary hypertension in the guinea pig effect of three levels of hypoxia. J Appl Physiol. 74:1993;916-921
28. Rumsey W.L., Abbott B.M., Bertelsen D.L., DeSiato M.A. Nitric oxide and endothelin in acute hypoxic pulmonary vasoconstriction and adaptation to chronic hypoxia. Adv Exp Med Biol. 428:1997;173-180
29. Rodman D.M., Yamaguchi T., Hasunuma K., O'Brien R.F., McMurtry I.F. Effects of hypoxia on endothelium-dependent relaxation of rat pulmonary artery. Am J Physiol. 258:1990;L207-214
30. Shaul P.W., Wells L.B., Horning K.M. Acute and prolonged hypoxia attenuate endothelial nitric oxide production in rat pulmonary arteries by different mechanisms. J Cardiovasc Pharmacol. 22:1993;819-827
31. Johns R.A., Linden J.M., Peach M.J. Endothelium-dependent relaxation and cyclic GMP accumulation in rabbit pulmonary artery are selectively impaired by moderate hypoxia. Circ Res. 65:1989;1508-1515
32. Hampl V., Cornfield D.N., Cowan N.J., Archer S.L. Hypoxia potentiates nitric oxide synthesis and transiently increases cytosolic calcium levels in pulmonary artery endothelial cells. Eur Respir J. 8:1995;515-522
33. Jones R.D., Morice A.H. The effect of the nitric oxide synthase inhibitor N-gamma-nitro-l-argine methyl ester on hypoxic pulmonary vasoconstriction. Eur J Pharmacol. 402:2000;111-117
34. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol. 274:1998;R577-595
35. Rakugi H., Tabuchi Y., Nakamaru M., et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun. 169:1990;973-977
36. Kourembanas S., Marsden P.A., McQuillan L.P., Faller D.V. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest. 88:1991;1054-1057
37. Wang Y., Coe Y., Toyoda O., Coceani F. Involvement of endothelin-1 in hypoxic pulmonary vasoconstriction in the lamb. J Physiol (Lond). 482:1995;421-434
38. Sato K., Morio Y., Morris K.G., Rodman D.M., McMurtry I.F. Mechanism of hypoxic pulmonary vasoconstriction involves ET(A) receptor-mediated inhibition of K(ATP) channel. Am J Physiol Lung Cell Mol Physiol. 278:2000;L434-442
39. B receptor antagonists, and protein kinase C inhibitor prevent acute hypoxic pulmonary vasoconstriction. Influence of potassium channels. J Cardiovasc Pharmacol. 41:2003;117-125
40. Wong J., Vanderford P.A., Winters J.W., et al. Endothelin-1 does not mediate acute hypoxic pulmonary vasoconstriction in the intact newborn lamb. J Cardiovasc Pharmacol. 22:(Suppl 8):1993;S262-266
41. Michiels C., Arnould T., Knott I., Dieu M., Remacle J. Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am J Physiol. 264:1993;C866-874
42. Madden M.C., Vender R.L., Friedman M. Effect of hypoxia on prostacyclin production in cultured pulmonary artery endothelium. Prostaglandins. 31:1986;1049-1062
43. Rodman D.M., Yamaguchi T., O'Brien R.F., McMurtry I.F. Hypoxic contraction of isolated rat pulmonary artery. J Pharmacol Exp Ther. 248:1989;52-59
44. Ertel W., Morrison M.H., Ayala A., Chaudry I.H. Hypoxemia in the absence of blood loss or significant hypotension causes inflammatory cytokine release. Am J Physiol. 269:1995;R160-166
45. Sheridan B.C., McIntyre R.C., Agrafojo J., et al. Neutrophil depletion attenuates endotoxin-induced dysfunction of cGMP-mediated pulmonary vasorelaxation. Am J Physiol. 271:1996;L820-828
46. Sheridan B.C., McIntyre R.C. Jr, Meldrum D.R., et al. Vinblastine attenuates endotoxin-induced impairment of cGMP-mediated pulmonary vasorelaxation. Shock. 6:1996;35-38
47. Sheridan B.C., McIntyre R.C. Jr, Moore E.E., et al. Neutrophils mediate pulmonary vasomotor dysfunction in endotoxin-induced acute lung injury. J Trauma. 42:1997;391-397
48. McIntyre R.C. Jr, Pulido E.J., Sheridan B., et al. Endotoxin differentially impairs receptor-mediated relaxation in rat isolated pulmonary and thoracic aortic vessels. J Trauma. 45:1998;862-867
49. Sheridan B.C., Dinarello C.A., Meldrum D.R., et al. Interleukin-11 attenuates pulmonary inflammation, and vasomotor dysfunction in endotoxin-induced lung injury. Am J Physiol. 277:1999;L861-867
50. Tamura D.Y., Moore E.E., Partrick D.A., et al. Acute hypoxemia in humans enhances the neutrophil inflammatory response. Shock. 17:2002;269-273
51. Kisala J.M., Ayala A., Stephan R.N., Chaudry I.H. A model of pulmonary atelectasis in rats activation of alveolar macrophage and cytokine release. Am J Physiol. 264:1993;R610-614
52. Johnson A., Ferro T.J. TNF-alpha augments pulmonary vasoconstriction via the inhibition of nitrovasodilator activity. J Appl Physiol. 73:1992;2483-2492
53. Stevens T., Janssen P.L., Tucker A. Acute and long-term TNF-alpha administration increases pulmonary vascular reactivity in isolated rat lungs. J Appl Physiol. 73:1992;708-712
54. Castaneda J., Isusi A., Tamayo L. Hypoxic pulmonary vasoconstriction increases during endotoxemia in the perfused rat lung. J Trauma. 50:2001;882-886
55. Liu S.F., Dewar A., Crawley D.E., Barnes P.J., Evans T.W. Effect of tumor necrosis factor on hypoxic pulmonary vasoconstriction. J Appl Physiol. 72:1992;1044-1049
56. Ziesche R., Petkov V., Williams J., et al. Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue. Proc Natl Acad Sci USA. 93:1996;12478-12483
57. Uzun O., Demiryurek A.T. Nuclear factor-kappaB inhibitors abolish hypoxic vasoconstriction in sheep-isolated pulmonary arteries. Eur J Pharmacol. 458:2003;171-174
58. 2+ release in hypoxic vasoconstriction of canine pulmonary artery. Br J Pharmacol. 122:1997;21-30
59. Barman S.A. Potassium channels modulate hypoxic pulmonary vasoconstriction. Am J Physiol. 275:1998;L64-70
60. Weir E.K., Archer S.L. The mechanism of acute hypoxic pulmonary vasoconstriction the tale of two channels. FASEB J. 9:1995;183-189
61. Post J.M., Hume J.R., Archer S.L., Weir E.K. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol. 262:1992;C882-890
62. 2+ release from intracellular stores is an initial step in hypoxic pulmonary vasoconstriction of rat pulmonary artery resistance vessels. Circulation. 96:1997;3647-3654
63. 2+, cyanide, and monocrotaline. J Appl Physiol. 71:1991;30-36
64. Weissmann N., Voswinckel R., Hardebusch T., et al. Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. Am J Physiol. 276:1999;L90-95
65. Barman S.A. Effect of protein kinase C inhibition on hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 280:2001;L888-895
66. Yuan X.J., Goldman W.F., Tod M.L., Rubin L.J., Blaustein M.P. Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol. 264:1993;L116-123
67. + channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest. 101:1998;2319-2330
68. Archer S.L., London B., Hampl V., et al. Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5. FASEB J. 15:2001;1801-1803
69. Dipp M., Nye P.C., Evans A.M. Hypoxic release of calcium from the sarcoplasmic reticulum of pulmonary artery smooth muscle. Am J Physiol Lung Cell Mol Physiol. 281:2001;L318-325
70. Marshall C., Mamary A.J., Verhoeven A.J., Marshall B.E. Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol. 15:1996;633-644
71. Wilson H.L., Dipp M., Thomas J.M., et al. ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase act as a redox sensor. A primary role for cyclic ADP-ribose in hypoxic pulmonary vasoconstriction. J Biol Chem. 276:2001;11180-11188
72. Kadletz M., Dignan R.J., Wechsler A.S. Reactivity to alpha agonists is heightened in immature porcine pulmonary arteries. Ann Thorac Surg. 61:1996;1359-1362
73. Pepke-Zaba J., Higenbottam T.W., Dinh-Xuan A.T., Stone D., Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 338:1991;1173-1174
74. Frostell C., Fratacci M.D., Wain J.C., Jones R., Zapol W.M. Inhaled nitric oxide a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 83:1991;2038-2047
75. Rossaint R., Falke K.J., Lopez F., et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 328:1993;399-405
76. Bender K.A., Alexander J.A., Enos J.M., Skimming J.W. Effects of inhaled nitric oxide in patients with hypoxemia and pulmonary hypertension after cardiac surgery. Am J Crit Care. 6:1997;127-131
77. Beghetti M., Habre W., Friedli B., Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J. 73:1995;65-68
78. Adatia I., Thompson J., Landzberg M., Wessel D.L. Inhaled nitric oxide in chronic obstructive lung disease. Lancet. 341:1993;307-308
79. Sitbon O., Brenot F., Denjean A., et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 151:1995;384-389
80. Sitbon O., Humbert M., Jagot J.L., et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 12:1998;265-270
81. Widlitz A., Barst R.J. Pulmonary arterial hypertension in children. Eur Respir J. 21:2003;155-176
82. Berner M., Beghetti M., Spahr-Schopfer I., Oberhansli I., Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol. 77:1996;532-535
83. Frostell C.G., Blomqvist H., Hedenstierna G., Lundberg J., Zapol W.M. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology. 78:1993;427-435
84. Walmrath D., Schneider T., Schermuly R., et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 153:1996;991-996
85. Gerlach H., Rossaint R., Pappert D., Falke K.J. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest. 23:1993;499-502
86. Dellinger R.P., Zimmerman J.L., Taylor R.W., et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 26:1998;15-23
87. Dupont H., Le Corre F., Fierobe L., et al. Efficiency of inhaled nitric oxide as rescue therapy during severe ARDS survival and factors associated with the first response. J Crit Care. 14:1999;107-113
88. Klinger JR. Inhaled nitric oxide in ARDS. Crit Care Clin 2002;18:45-68, vi
89. Gow A.J., Thom S.R., Ischiropoulos H. Nitric oxide and peroxynitrite-mediated pulmonary cell death. Am J Physiol. 274:1998;L112-118
90. Nagaya N., Uematsu M., Oya H., et al. Short-term oral administration of l-arginine improves hemodynamics, and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 163:2001;887-891
91. Mitani Y., Maruyama K., Sakurai M. Prolonged administration of l-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation. 96:1997;689-697
92. Jacobs B.R., Brilli R.J., Ballard E.T., Passerini D.J., Smith D.J. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. Am J Respir Crit Care Med. 158:1998;1536-1542
93. Jacobs B.R., Smith D.J., Zingarelli B., et al. Soluble nitric oxide donor and surfactant improve oxygenation and pulmonary hypertension in porcine lung injury. Nitric Oxide. 4:2000;412-422
94. Schutte H., Grimminger F., Otterbein J., et al. Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation. J Pharmacol Exp Ther. 282:1997;985-994
95. Moya M.P., Gow A.J., McMahon T.J., et al. S-nitrosothiol repletion by an inhaled gas regulates pulmonary function. Proc Natl Acad Sci USA. 98:2001;5792-5797
96. 2 and prostacyclin in children with cyanotic congenital heart disease. Br Heart J. 69:1993;179-182
97. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 334:1996;296-302
98. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinol, a prostacyclin analogue, in patients with pulmonary arterial hypertension a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 165:2002;800-804
99. Hoeper M.M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 342:2000;1866-1870
100. Langleben D., DeMarchie M., Laporta D., et al. Endothelin-1 in acute lung injury, and the adult respiratory distress syndrome. Am Rev Respir Dis. 148:1993;1646-1650
101. Eddahibi S., Raffestin B., Clozel M., Levame M., Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol. 268:1995;H828-835
102. Chen S.J., Chen Y.F., Meng Q.C., et al. Endothelin-receptor antagonist bosentan prevents, and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 79:1995;2122-2131
103. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension a randomised placebo-controlled study. Lancet. 358:2001;1119-1123
104. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation. 107:2003;2037-2044
105. Matschurat S., Knies U.E., Person V., et al. Regulation of EMAP II by hypoxia. Am J Pathol. 162:2003;93-103